

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

Rapid and Quantitative Detection of Human Antibodies Against the 2019 Novel Coronavirus SARS CoV2 and its Variants as a Result of Vaccination and Infection

Benjamin Taubner¹, Ruben Peredo-Wende², Ananthakrishnan Ramani³, Gurpreet Singh⁴, Klemen Strle⁵,
Nathaniel C. Cady¹

¹College of Nanoscale Science & Engineering, SUNY Polytechnic Institute, Albany, NY, USA

²Division of Rheumatology Albany Medical Center, Albany, NY, 12208

³Division of Infectious Diseases Albany Medical Center, Albany, NY 12208

⁴Internal Medicine Albany Medical Center, Albany, NY 12208

⁵Wadsworth Center, New York State Department of Health, Albany, NY, USA and School of Public Health,
University at Albany, Albany, NY, USA

Corresponding Author: Nathaniel C. Cady, PhD
SUNY Polytechnic Institute
ncady@sunypoly.edu

27

28 **ABSTRACT**

29 Measuring the antibody response to 2019 SARS CoV2 is critical for diagnostic purposes, monitoring the
30 prevalence of infection, and for gauging the efficacy of the worldwide vaccination effort COVID-19. In this
31 study, a microchip-based grating coupled fluorescent plasmonic (GC-FP) assay was used to measure antibody
32 levels that resulted from COVID-19 infection and vaccination. In addition, we measured the relative antibody
33 binding towards antigens from variants CoV2 virus variants, strains B.1.1.7 (UK) and B.1.351 (S. African).
34 Antibody levels against multiple antigens within the SARS CoV2 spike protein were significantly elevated for
35 both vaccinated and infected individuals, while those against the nucleocapsid (N) protein were only elevated
36 for infected individuals. GC-FP was effective for monitoring the IgG-based serological response to vaccination
37 throughout the vaccination sequence, and could also resolve acute (within hours) increases in antibody levels. A
38 significant decrease in antibody binding to antigens from the B.1.351 variant, but not B.1.1.7, was observed for
39 all vaccinated subjects when measured by GC-FP as compared to the 2019 SARS CoV2 antigens. These results
40 were corroborated by competitive ELISA assay. Collectively, the findings suggest that GC-FP is a viable, rapid,
41 and accurate method for measuring both overall antibody levels to CoV2 and relative antibody binding to viral
42 variants during infection or vaccination.

43

44 **KEYWORDS**

45 COVID-19, CoV2, antibody, biosensor, plasmonic, quantitative, multiplex, vaccine, variant, diagnostic,
46 detection

47

48

49 **INTRODUCTION**

50 The 2019 novel coronavirus, SARS CoV2 (COVID-19) has resulted in millions of deaths worldwide, and
51 has spurred the development of novel diagnostic strategies, detection technologies, and vaccination approaches.
52 Monitoring an individual's antibody responses to CoV2 antigens has become paramount from an
53 epidemiological perspective, but also as a means of determining the efficacy of vaccination. By measuring the

54 levels of antibodies (primarily IgG) in human blood or other bodily fluids, an individual's prior infection
55 history, as well as their serological response to vaccination can be elucidated. Monitoring the stability and/or
56 decline of antibody levels over time is important in estimating how long individuals will retain immunity (1).

57 Beyond assessing human serological response to infection or vaccination, it is important to understand how
58 an individual's immune system will respond to a growing number of novel CoV2 variants. A core area of
59 concern is mutations in the spike protein, which could interfere with antibody binding, and subsequently affect
60 the blockade (neutralization) of viral entry into human cells via the ACE2 receptor (2). This could ultimately
61 result in breakthrough infections for individuals who were previously infected or vaccinated (2). Recent studies
62 have shown that emerging variants in the United Kingdom (B.1.1.7) and South Africa (B.1.351) are not as
63 effectively neutralized by blood serum from vaccinated individuals, nor from those who were previously
64 infected with the original 2019 SARS CoV2 strain (2-4). This is also an area of concern for variants emerging
65 in other regions, including Brazil and India (5, 6). This highlights the need for sensitive, specific, high-
66 throughput assays to monitor antibody levels and predict effectiveness.

67 Multiplexed quantitative serological assays; allow both the determination of antibody levels in response
68 to infection and vaccination, and the ability to assess relative antibody neutralizing capacity, provide an
69 attractive diagnostic solution. Established methods of assessing antibody response to SARS CoV2 and its
70 variants include cell-based viral neutralization assays (2, 3, 7, 8) and competitive *in vitro* binding assays such as
71 ELISA (9, 10). Previously we demonstrated a grating-coupled fluorescent plasmonic (GC-FP) biosensor
72 platform for rapid (30 min), quantitative, multiplexed detection of human antibody response to both Lyme
73 disease and COVID-19 infection (11, 12). The GC-FP detection ratio (ratio of antibody binding to target
74 antigens vs. negative control proteins) for human serum and dried blood spot samples correlated strongly with
75 standard antibody testing approaches, including microsphere immunoassay (MIA) and ELISA (12). Notably, we
76 found that dried blood spot samples as well as more traditional blood serum samples could yield high sensitivity
77 and selectivity for diagnosing prior COVID-19 infection.

78 In the study presented here, we modified GC-FP detection microchips to include additional antigens from
79 variant strains of SARS CoV2, including B.1.1.7 and B.1.351. Using these new detection microchips, we were
80 able to simultaneously monitor antibody levels against multiple 2019 SARS CoV2 antigens for individuals
81 throughout the vaccination sequence, and for all three vaccine types currently approved for use in the United
82 States: Pfizer-BioNTech (13), Moderna (14) and Johnson & Johnson (15). We also assessed the relative
83 binding of antibodies to original and variant strains of SARS CoV2 antigens for multiple exposure scenarios
84 including: 1) acute severe (hospitalized) infection, 2) mild infections that did not lead to hospitalization, 3)
85 vaccination with all three vaccines, 4) and a combination of prior infection and vaccination. Our results
86 demonstrate that GC-FP is an effective and sensitive method to monitor antibody levels in response to
87 vaccination, and can determine relative antibody binding levels to original and variant 2019 SARS CoV2
88 antigens, all in a single, rapid test.

90 **MATERIALS AND METHODS**

91 *Materials*

92 Nucleocapsid protein (N), the S1 fragment of the spike protein (S1), the extracellular domain of the
93 spike protein (S1S2), the receptor binding domain of the spike protein (RBD) for the 2019 SARS CoV2 virus,
94 S1 variant antigens, RBD variant antigens, and human serum albumin (HSA) were all obtained from Sino
95 Biological, Inc. (Table 1). Positive control protein, human IgG protein (Hum IgG), SuperBlock blocking buffer
96 and phosphate buffered saline (PBS) were obtained from ThermoFisher Scientific. PBS-TWEEN (PBS-T)
97 solution consisting of PBS + 0.05% v/v TWEEN-20 (Sigma-Aldrich) was prepared on a daily basis for all
98 experiments. Alexa Fluor 647 labeled anti-human IgG (heavy and light chain) were obtained from
99 Invitrogen/ThermoFisher Scientific. ACE2 competitive ELISA testing was performed using COVID-19 ACE2
100 testing kits from RayBiotech (COVID-19 Spike Variant-ACE2 Binding Assay Kit).

102 *Grating-Coupled Fluorescent Plasmonic (GC-FP) Biosensor Chip Preparation*

103 Gold coated grating-coupled fluorescent plasmonic (GC-FP) biosensor chips were fabricated as
104 described our previous work (11, 12, 16). GC-FP chips were also printed as described previously (12). A map of
105 the protein/antigen spots is shown in the supplementary data, Figure S1.

106
107 **Table 1.** Proteins and peptides used for generating GC-FP detection microchips.

Antigen/Protein	Source
Human IgG (positive control)	Thermo Fisher
Human Serum Albumin / HSA (negative control)	Sino Biological
2019 SARS CoV2 Nucleocapsid (N)	Sino Biological
2019 SARS CoV2 RBD (RBD)	Sino Biological
2019 SARS CoV2 S1S2+ECD (S1S2)	Sino Biological
2019 SARS CoV2 S1 (S1)	Sino Biological
SARS CoV2 RBD – B.1.1.7 (N501Y)	Sino Biological
SARS CoV2 RBD – B.1.351 (K417N, E484K, N501Y)	Sino Biological
SARS CoV2 S1 – B.1.351 (K417N, E484K, N501Y, D614G)	Sino Biological
SARS CoV2 S1 – B.1.1.7 (Δ HV69-70, Δ Y144, N501Y, A570D, D614G, P681H)	Sino Biological

108
109 ***Biological Samples***

110 Serum samples were collected from COVID-19 patients admitted to Albany Medical Center between
111 October and December 2020 who enrolled in a study “Defining genetic and immune factors in COVID-19
112 severity.” All patients had a positive RT-PCR test for CoV2 and were hospitalized due to severity of their
113 illness. Sera were processed on the day of collection and placed into -80C freezer until analyses. The study was
114 approved by the IRB at Albany Medical Center (Protocol # 5929).

115 Dried blood samples were collected by the finger stick method. Lancet devices (27 ga.) and Whatman
116 903 protein saver collection cards were sent to volunteers with instructions and consent form approved by the
117 SUNY Polytechnic Institute Institutional Review Board (protocol #IRB-2020-10 and #IRB-2021-2). Blood
118 droplets were collected, allowed to dry, and then either hand delivered or mailed (via US Postal Service) to
119 SUNY Polytechnic Institute. Following receipt of DBS samples, a 6 mm diameter biopsy punch was used to
120 remove samples from the collection cards, which were then soaked in 500 μ l of PBS-T ~12 hr at 4 °C with
121 rocking. Samples were collected from 1) participants who had no known exposure to COVID-19 and/or tested
122 negative for COVID-19 infection, 2) vaccinated individuals at different time points throughout vaccination

123 sequence, including pre-vaccination, at the second dose, and two weeks after the second dose, 3) vaccinated
124 individuals at a single time point, a minimum of 2 weeks after final vaccination dose, and 4) vaccinated
125 individuals who were previously diagnosed with COVID-19 infection via RT-PCR. The age, gender, and
126 exposure/vaccination information for all participants represented in this work are listed in supplementary tables
127 S1 and S2.

128 ***GC-FP Detection Assay and ACE2 Competitive Assay***

129 GC-FP microchips were processed using the same conditions described previously (12). Total assay
130 time from sample introduction to chip imaging was 30 min. For serum testing, a standard dilution of serum in
131 PBS-T (1:50) was used. For dried blood spot testing, undiluted extract (from extraction in 500 μ l PBS-T) from
132 the 6 mm diameter segment of the blood collection card was used in place of serum. Ciencia image analysis
133 LabView software was used to define a region of interest (ROI) for each individual spot on the GC-FP
134 biosensor chip and the fluorescence intensity of each spot was measured. The fluorescence intensity of all spots
135 was normalized to the human IgG (Hum IgG) internal control spots on each chip, to account for variability
136 between individual chips and individual experiments, generating a “GC-FP detection ratio” for every
137 protein/antigen included in the GC-FP microchip (12):

138

$$139 \text{ GC-FP Detection Ratio} = \frac{\bar{x} \text{ target spot intensity}}{(\bar{x} \text{ neg.ctrl.spot intensity}) + (3\sigma \text{ neg.ctrl.spot intensity})}$$

140

141 To determine if GC-FP antibody binding data for 2019 SARS CoV2 vs. B.1.1.7 and B.1.351 variant
142 antigens was consistent with standard methods, an ELISA-based ACE2 competitive binding assay (Ray
143 Biotech) was used, as per the manufacturer’s instructions. Additional details are provided in the supplementary
144 information. Percent binding inhibition was calculated for each sample by the following method:

145

$$146 \% \text{ Binding Inhibition} = 1 - \left(\frac{\bar{x} \text{ sample absorbance at 450 nm}}{(\bar{x} \text{ positive control absorbance at 450 nm})} \right)$$

147


148 ***Data Analysis***

GC-FP diagnostic ratio data and percent binding inhibition data for the ACE2 competitive assay were analyzed using GraphPad Prism 8.0 software (ROC analysis, correlation, and statistical analysis).

RESULTS AND DISCUSSION

Determination of Human Antibody Response to 2019 SARS CoV2 Vaccination

Dried blood samples from individuals with no known previous COVID-19 infection (n = 52) and individuals two weeks past full vaccination with either Pfizer-BioNTech (n = 17), Moderna (n = 8), or Johnson & Johnson (n = 9) vaccines were tested using the GC-FP assay to determine antibody levels against three SARS CoV2 spike protein antigens (S1, S1S2, RBD) and the nucleocapsid protein (N). As we described in previous work (12), the GC-FP diagnostic ratio provides a quantitative measure of antibody levels and correlates well with established serological techniques such as MIA and ELISA. In the current work, antibody levels in vaccinated individuals were significantly elevated for all spike antigens (Mann-Whitney, $p < 0.0001$), with highest mean increase in antibody levels observed for the S1 and RBD antigens (supplementary information, Figure S2A). A nominal increase in antibody levels was also observed against the S1S2 antigen and N protein, but reactivity to these antigens was significantly less than for S1 and RBD. Receiver operator characteristic (ROC) analysis on these data (supplementary information, Figure S2B) showed that antibody levels against S1 were diagnostic for vaccination status with 61% sensitivity and 100% specificity, while levels against RBD were diagnostic with 80% sensitivity and 100% specificity. Antibody levels for S1S2 and N resulted in low area under the curve (AUC) results from the ROC analysis and were considered insufficient for diagnostic purposes. Because all three vaccines should only elicit immunological response to the SARS CoV2 spike antigen, the lack of a diagnostic antibody response for the N protein was expected.



173

174 **Figure 1.** Human IgG levels against SARS CoV2 antigens throughout the vaccination sequence (Pfizer-BioNTech) for 10
175 different subjects, collected pre-vaccination, at the time of the 2nd dose of vaccine, and 2 weeks after the 2nd dose of
176 vaccine. One-way ANOVA followed by Dunnett's multiple comparison testing was performed (*p = 0.03, ** p = 0.002,
177 *** p = 0.0002, **** p < 0.0001).

178

179 Dried blood samples were also tested using GC-FP for ten (10) individuals throughout their vaccination
180 sequence with the Pfizer-BioNTech vaccine (pre-vaccine, at the time of the 2st dose, and 2 weeks after 2nd
181 dose). Antibody levels (as determined by GC-FP detection ratio) were significantly higher for the S1, S1S2,
182 and RBD antigens at both the time of the 2nd dose and 2 weeks after the second dose (Figure 1). As expected,
183 antibodies against the N antigen were not detected at any of these time points, since all three vaccines utilize the
184 spike antigen (and not the N antigen) to induce immune response.

185

GC-FP was also used to detect antibody levels against SARS CoV2 antigens and antigens from variants

186

B.1.1.7 and B.1.351, at additional time points throughout the vaccination sequence (Pfizer-BioNTech) for an

187

individual subject (Figure 2). Increased antibody levels were observed against spike antigens (S1, S1S2, and

188

RBD) within 1 week after the 1st dose. Antibody levels then declined slightly until the 2nd dose, when they

189

increased at both 10 hrs and 1 week post 2nd dose. Finally, levels declined at 2 weeks post 2nd dose. The changes

190

in antibody levels correlate well with what is expected during the vaccination sequence, wherein antibody levels

191

should increase after each dose, but then decline to a stable level over time. Antibody responses to S1 or RBD

192

from CoV2 UK variants were similar as antigens from the original 2019 CoV2, but these responses were

193

dramatically reduced to S. African variants (RBD and S1 from strain B.1.351) throughout the vaccination


194

course. These data illustrate the potential to quantitatively measure antibody response to vaccination with high

195

resolution (through time).

196



197

198

Figure 2. Human IgG levels for a single individual over the course of vaccination with the Pfizer-BioNTech vaccine, measured with GC-FP.


199

200

201 ***Determination of Human Antibody Binding to 2019 SARS CoV2 Antigens and its Variants***

202 GC-FP testing was performed on serum from acutely infected (hospitalized) individuals and dried blood
203 samples from individuals who were: 1) Uninfected/pre-vaccine - had no known prior infection with COVID-19
204 and were not vaccinated, 2) Hospitalized - infected with COVID-19 and hospitalized due to infection, 3) Non-
205 hospitalized - were infected with COVID-19 and at least 4 weeks post recovery, 4) Vaccinated (Pfizer,
206 Moderna, J&J - were at least 2 weeks past final dose of Pfizer-BioNTech, Moderna or Johnson & Johnson
207 vaccine, or 5) CoV2 positive & Vaccinated - previously infected with COVID-19 and then fully vaccinated with
208 Pfizer-BioNTech or Moderna vaccine. Results of this study are shown in Figure 3. As compared to
209 uninfected/unvaccinated individuals, vaccinated individuals (with and without prior infection) had significantly
210 higher antibody levels against S1 and RBD antigens. Acutely infected (hospitalized) individuals had elevated
211 antibody levels for S1S2 and N antigens, while non-hospitalized patients only showed increased antibody levels
212 against N. Notably, individuals who were vaccinated after prior infection had the highest mean antibody levels
213 against S1 and RBD. This is consistent with the fact that these individuals were effectively exposed to the spike
214 antigen at three different time points (during infection and at the 1st and 2nd doses of vaccine).

215




216

217 **Figure 3.** IgG levels against SARS CoV2 antigens for uninfected, previously infected, and vaccinated individuals.
218 Uninfected samples were collected prior to vaccination, from individuals who reported no prior COVID-19 symptoms,
219 and tested negative via PCR and/or antibody testing (n = 42). Other samples were from PCR confirmed COVID-19
220 positive subjects who were hospitalized (n = 3), PCR confirmed COVID-19 positive subjects who were not hospitalized
221 CoV2 (n = 5), and previously COVID-19 positive subjects who received subsequent vaccination (n = 9). Samples were
222 also collected from subjects who were at least 2 weeks past full vaccination with Pfizer-BioNTech (n = 17), Moderna (n =
223 8), or 2 weeks after receiving the Johnson & Johnson vaccine (n = 9). One-way ANOVA followed by Dunnett's multiple
224 comparison testing was performed (*p = 0.03, ** p = 0.002, *** p = 0.0002, **** p < 0.0001).

225

226 Between individual subjects, antibody levels were highly variable, regardless of the mode of COVID-19
227 exposure or vaccination status (Figure 3 and supplementary data Figure S3). To account for these differences,
228 and to elucidate relative antibody binding levels to variant antigens vs. 2019 SARS CoV2 antigens, the fold-


229 difference (binding to variant antigen vs. 2019 SARS CoV2 antigen) in antibody levels between variant
230 antigens and the 2019 SARS CoV2 antigens was plotted (Figure 4). For all vaccinated individuals, antibody
231 binding to B.1.351 antigens (both RBD and S1) was reduced vs. 2019 SARS CoV2 antigens. Antibody binding
232 to B.1.1.7 antigens was either equivalent to, or slightly higher than 2019 SARS CoV2 antigens for these same
233 individuals. For previously infected individuals (hospitalized and non-hospitalized) there were only minor
234 differences in antibody levels for variant antigens vs. 2019 SARS CoV2 antigens ($p > 0.03$ or not significant).



235
236 **Figure 4.** Fold-difference in antibody levels against antigens from SARS CoV2 variant strains B.1.1.7 and B.1.351 vs.
237 antigens from the original 2019 SARS CoV2 strain. Samples included those from individuals who were hospitalized (n =
238 3); non-hospitalized CoV2 positive (n = 5); previously CoV2 positive with subsequent vaccination (n = 9); and at least 2
239 weeks past vaccination with Pfizer-BioNTech (n = 17), Moderna (n = 8), or Johnson & Johnson vaccine (n = 9). One-way
240 ANOVA followed by Dunnett's multiple comparison testing was performed (* $p = 0.03$, ** $p = 0.002$, *** $p = 0.0002$,
241 **** $p < 0.0001$).

242

243 To determine if these results were due to differences in antibody affinity towards variant vs. 2019 SARS
244 CoV2 antigens, we compared the GC-FP results to a competitive ELISA in which blood samples were mixed
245 with ACE2 receptor protein (the cellular target of SARS CoV2) and allowed to competitively bind to 2019
246 SARS CoV2 RBD antigen, or the B.1.1.7 and B.1.351 RBD variants. Competitive ELISA results were similar
247 to GC-FP results (Figure 5, A&B), showing both significantly reduced antibody binding (GC-FP) and reduced
248 binding inhibition (competitive ELISA) for the B.1.351 RBD variant. When quantitative dilution testing was
249 performed for a single Pfizer-BioNTech-vaccinated individual and a single acutely infected (hospitalized)
250 individual, significant differences in binding inhibition were observed for both B.1.1.7 and B.1.351 RBD
251 variants (Figure 5,C&D). When the fold-difference in antibody binding (GC-FP) and percent binding inhibition
252 (competitive ELISA) were compared, there was close correlation between the two methods (Figure 5, E&F, and
253 supplementary data Figure S4). Values plotted in Figure 5, E&F were shown to be correlated (Pearson $r = 0.89$,
254 $p = 0.02$, supplementary Figure S4), suggesting that GC-FP has utility for assessing relative antibody binding
255 levels and/or avidity to antigens from 2019 SARS CoV2 and variant strains of the virus.



267

268

Figure 5. A&B) IgG levels from dried blood spots measured by GC-FP diagnostic ratio compared to competitive ELISA by eluate from the same dried blood spot samples. Both GC-FP and ACE2 competitive binding were performed for RBD antigen from the original 2019 SARS CoV2 and the variant strains B.1.1.7 and B.1.351. Testing was performed with dried blood spots collected from vaccinated subjects (3 Pfizer-BioNTech, 3 Moderna, 2 Johnson & Johnson) and subjects who were both previously infected and then vaccinated with Pfizer-BioNTech or Moderna vaccines (n = 3). One-way ANOVA followed by Dunnett's multiple comparison testing was performed (*p = 0.03, ** p = 0.002, *** p = 0.0002, **** p < 0.0001). Percent ACE2 binding inhibition from competitive ELISA assay is shown for a dried blood spot sample (C) from a Pfizer-BioNTech vaccinated subject and blood serum from a hospitalized, COVID-positive subject (D). Vertical dotted lines represent the dilution factor used in the corresponding GC-FP test for each sample. Fold difference in binding inhibition and fold difference in GC-FP diagnostic ratio was plotted for variant antigens (RBD B.1.1.7 and RBD B.1.351) vs. RBD 2019 CoV2 (E & F).

280

281

282 **DISCUSSION**

283 We previously demonstrated that GC-FP is a rapid and accurate technique for detection of antibodies that
284 result from COVID-19 infection (12). In the current study, we extended this work to show that GC-FP can
285 measure the level of antibodies resulting from vaccination, and that it can quantitatively measure the increase in
286 antibody levels during the course of vaccination for multiple target antigens. Using ROC analysis, GC-FP
287 diagnostic ratio thresholds could be established to yield a clear cut-off for determining whether or not an
288 individual has been vaccinated. When using the RBD antigen, this results in 80% sensitivity and 100%
289 specificity for all three of the currently approved vaccines (Pfizer-BioNTech, Moderna and Johnson &
290 Johnson). Furthermore, our results show that antibody levels can be measured with high resolution throughout
291 the course of vaccination, making it a useful tool to track the progression of an individual's serological response
292 to a vaccine. Highlighting the sensitivity of the GC-FP approach, we were able to detect increasing levels of
293 antibodies within just 10 hrs of an individual's second dose of the Pfizer-BioNTech vaccine (Figure 2).

294 Beyond determination of vaccination status and serological response to vaccination, the multiplexed nature
295 of GC-FP makes it highly amenable to measuring antibody binding to multiple antigens from both the original
296 2019 SARS CoV2 virus and the emerging variants of this virus. This is extremely important as variants of the
297 virus continue to emerge (5, 6). For example, GC-FP results indicate reduced antibody binding to the RBD and
298 S1 antigens of the B.1.351 (S. African) variant, which was further confirmed through competitive ELISA-based
299 testing (Figure 5). When individual samples were evaluated by GC-FP and competitive ELISA, reduced
300 antibody binding to antigens from both the B.1.1.7 (UK) and B.1.351 variants was observed.

301 The results of the present study, together with our previous demonstration of GC-FP for COVID-19
302 antibody detection (12) compare favorably to similar studies using multiplexed, array-based techniques. Using a
303 plasmonic-based approach, Liu et al. demonstrated high throughput detection of COVID-19 antibodies from
304 human serum and saliva (17). This approach requires significantly more time than GC-FP (~2 hrs vs. 30 min)
305 but it has the advantage of measuring the relative avidity of antibodies towards target antigens. In another study,
306 Swank et al., demonstrated an elegant, high throughput microfluidic approach to COVID-19 antibody detection.

307 While this approach enables extremely high throughput, it is limited in the number of target antigens that can be
308 implemented, and requires complicated printing of human blood samples to prepare detection chips.

309 In the work presented here, we have demonstrated that GC-FP based, multiplexed detection of antibody
310 binding from human blood is a useful tool for determining an individual's response to vaccination and the
311 relative binding of antibodies to variants of the 2019 SARS CoV2 virus. When considering the rapid time to
312 result (30 min) for the GC-FP assay and the ability to target a large number of antigens at once, this represents a
313 powerful tool for continued management of the global COVID-19 pandemic, and with broad applicability to
314 other diseases and vaccines.

315

316

317

318 **REFERENCES CITED**

- 319 1. Chia WN, Zhu F, Ong SWX, Young BE, Fong SW, Le Bert N, Tan CW, Tiu C, Zhang J, Tan SY, Pada S, Chan YH,
320 Tham CYL, Kunasegaran K, Chen MI, Low JGH, Leo YS, Renia L, Bertoletti A, Ng LFP, Lye DC, Wang LF. 2021.
321 Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. *Lancet*
322 *Microbe* 2:E240-E249.
- 323 2. Hoffmann M, Arora P, Groß R, Seidel A, Hörnich BF, Hahn AS, Krüger N, Graichen L, Hofmann-Winkler H, Kempf
324 A, Winkler MS, Schulz S, Jäck HM, Jahrsdörfer B, Schrezenmeier H, Müller M, Kleger A, Münch J, Pöhlmann S.
325 2021. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. *Cell* 184:2384-2393.e12.
- 326 3. Xie X, Liu Y, Liu J, Zhang X, Zou J, Fontes-Garfias CR, Xia H, Swanson KA, Cutler M, Cooper D, Menachery VD,
327 Weaver SC, Dormitzer PR, Shi PY. 2021. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y
328 variants by BNT162b2 vaccine-elicited sera. *Nat Med* 27:620-621.
- 329 4. Chang X, Augusto GS, Liu X, Kündig TM, Vogel M, Mohsen MO, Bachmann MF. 2021. BNT162b2 mRNA
330 COVID-19 vaccine induces antibodies of broader cross-reactivity than natural infection but recognition of mutant
331 viruses is up to 10-fold reduced. *bioRxiv* doi:10.1101/2021.03.13.435222:2021.03.13.435222.
- 332 5. Mahase E. 2021. Covid-19: What new variants are emerging and how are they being investigated? *BMJ* 372:n158.
- 333 6. Wise J. 2021. Covid-19: UK cases of variant from India rise by 160% in a week. *BMJ* 373:n1315.
- 334 7. Muruato AE, Fontes-Garfias CR, Ren P, Garcia-Blanco MA, Menachery VD, Xie X, Shi PY. 2020. A high-
335 throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. *Nat Commun* 11:4059.
- 336 8. Tan CW, Chia WN, Qin X, Liu P, Chen MI, Tiu C, Hu Z, Chen VC, Young BE, Sia WR, Tan YJ, Foo R, Yi Y, Lye
337 DC, Anderson DE, Wang LF. 2020. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated
338 blockage of ACE2-spike protein-protein interaction. *Nat Biotechnol* 38:1073-1078.
- 339 9. Valdivia A, Torres I, Latorre V, Francés-Gómez C, Albert E, Gozalbo-Rovira R, Alcaraz MJ, Buesa J, Rodríguez-
340 Díaz J, Geller R, Navarro D. 2021. Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from
341 hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays. *Eur J Clin*
342 *Microbiol Infect Dis* 40:485-494.
- 343 10. Peterhoff D, Glück V, Vogel M, Schuster P, Schütz A, Neubert P, Albert V, Frisch S, Kiessling M, Pervan P, Werner
344 M, Ritter N, Babl L, Deichner M, Hanses F, Lubnow M, Müller T, Lunz D, Hitzenbichler F, Audebert F, Hähnel V,
345 Offner R, Müller M, Schmid S, Burkhardt R, Glück T, Koller M, Niller HH, Graf B, Salzberger B, Wenzel JJ, Jantsch
346 J, Gessner A, Schmidt B, Wagner R. 2021. A highly specific and sensitive serological assay detects SARS-CoV-2
347 antibody levels in COVID-19 patients that correlate with neutralization. *Infection* 49:75-82.
- 348 11. Chou E, Lasek-Nesselquist E, Taubner B, Pilar A, Guignon E, Page W, Lin YP, Cady NC. 2020. A fluorescent
349 plasmonic biochip assay for multiplex screening of diagnostic serum antibody targets in human Lyme disease. *PLoS*
350 *One* 15:e0228772.
- 351 12. Cady NC, Tokranova N, Minor A, Nikvand N, Strle K, Lee WT, Page W, Guignon E, Pilar A, Gibson GN. 2021.
352 Multiplexed detection and quantification of human antibody response to COVID-19 infection using a plasmon
353 enhanced biosensor platform. *Biosens Bioelectron* 171:112679.
- 354 13. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini
355 C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW, Hammitt LL, Türeci
356 Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC, Group CCT.
357 2020. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* 383:2603-2615.
- 358 14. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Roupheal N, Creech CB,
359 McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H,
360 Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C,
361 Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T, Group CS. 2021. Efficacy and Safety of the mRNA-
362 1273 SARS-CoV-2 Vaccine. *N Engl J Med* 384:403-416.
- 363 15. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C, Fennema H,
364 Spiessens B, Offergeld K, Scheper G, Taylor KL, Robb ML, Treanor J, Barouch DH, Stoddard J, Ryser MF,
365 Marovich MA, Neuzil KM, Corey L, Cauwenberghs N, Tanner T, Hardt K, Ruiz-Guiñazú J, Le Gars M,


- 366 Schuitemaker H, Van Hoof J, Struyf F, Dougouih M, Group ES. 2021. Safety and Efficacy of Single-Dose
367 Ad26.COV2.S Vaccine against Covid-19. *N Engl J Med* 384:2187-2201.
- 368 16. Chou E, Pilar A, Guignon E, Page W, Lin Y-P, Cady N. 2019. Rapid and multiplexed detection of Lyme disease
369 using a grating coupled-fluorescent plasmonics (GC-FP) biosensor platform. *SPIE BiOS* 10895.
- 370 17. Liu T, Hsiung J, Zhao S, Kost J, Sreedhar D, Hanson CV, Olson K, Keare D, Chang ST, Bliden KP, Gurbel PA,
371 Tantry US, Roche J, Press C, Boggs J, Rodriguez-Soto JP, Montoya JG, Tang M, Dai H. 2020. Quantification of
372 antibody avidities and accurate detection of SARS-CoV-2 antibodies in serum and saliva on plasmonic substrates. *Nat*
373 *Biomed Eng* 4:1188-1196.

374


Table 1. Proteins and peptides used for generating GC-FP detection microchips.

Antigen/Protein	Source
Human IgG (positive control)	Thermo Fisher
Human Serum Albumin / HSA (negative control)	Sino Biological
2019 SARS CoV2 Nucleocapsid (N)	Sino Biological
2019 SARS CoV2 RBD (RBD)	Sino Biological
2019 SARS CoV2 S1S2+ECD (S1S2)	Sino Biological
2019 SARS CoV2 S1 (S1)	Sino Biological
SARS CoV2 RBD – B.1.1.7 (N501Y)	Sino Biological
SARS CoV2 RBD – B.1.351 (K417N, E484K, N501Y)	Sino Biological
SARS CoV2 S1 – B.1.351 (K417N, E484K, N501Y, D614G)	Sino Biological
SARS CoV2 S1 – B.1.1.7 (Δ HV69-70, Δ Y144, N501Y, A570D, D614G, P681H)	Sino Biological


S1 - 2019 CoV2




S1S2 - 2019 CoV2




RBD - 2019 CoV2




N - 2019 CoV2




IgG Levels through Vaccination Sequence (Pfizer)




S1 - 2019 CoV2




S1S2 - 2019 CoV2




RBD - 2019 CoV2




N - 2019 CoV2




CoV2 Positive
(Hospitalized)




CoV2 Positive
(non-Hospitalized)




CoV2 Positive
(Vaccinated)




Vaccinated
(Pfizer)




Vaccinated
(Moderna)




Vaccinated
(J&J)




A ACE2 Competitive Binding Assay (Vaccinated Subjects)




B GC-FP (Vaccinated Subjects)




C Vaccinated (Pfizer) (Dried Blood Spot)



D CoV2 Positive (Hospitalized) (Serum)



E



F

